TABLE 1:
Case | Diagnosis | Age | Sex | Braak Stage | APOE | PMD |
---|---|---|---|---|---|---|
1273 | Control | 68 | M | 2 | 3/3 | 10 |
2522 | Control | 89 | F | 2 | 3/3 | 4 |
2152 | Control | 52 | F | 3 | NA | 14 |
1172 | Control | 77 | M | n/a | 3/3 | 13 |
2234 | Control | 68 | F | 2 | NA | 12 |
2151 | Control | 72 | M | 2 | 3/3 | 10 |
719 | Control | 66 | M | NA | NA | 10 |
2775 | Control | 88 | F | 2 | NA | 9 |
107 | Control | 71 | M | n/a | NA | 14 |
1517 | Control | 71 | F | 2 | 4/4 | 16 |
2066 | Control | 88 | M | 4 | 2/3 | 17.5 |
1591 | Control | 94 | M | 3 | 3/4 | 16 |
1104 | AsymAD | 82 | F | 2 | 3/4 | 14 |
2203 | AsymAD | 86 | M | 4 | NA | 8 |
2125* | AsymAD | 94 | M | 5 | 3/3 | 6 |
2167 | AsymAD | 92 | F | 5 | 3/3 | 13.5 |
1734 | AsymAD | 92 | F | 4 | 3/3 | 12 |
2880 | AsymAD | 85 | F | 5 | NA | 27 |
2190* | AsymAD | 92 | M | 6 | 3/3 | 8.5 |
1751 | AsymAD | 79 | M | 3 | NA | 22 |
2102 | AsymAD | 87 | M | 3 | 3/3 | 15 |
1421 | AsymAD | 94 | M | 4 | 3/3 | 14 |
2069 | AsymAD | 92 | F | 4 | 3/3 | 18 |
2176 | AD | 73 | M | 5 | 4/4 | 7 |
1430 | AD | 96 | M | 5 | 3/3 | n/a |
2175 | AD | 88 | F | 5 | NA | 11.5 |
2059 | AD | 76 | M | 6 | NA | 15 |
2574 | AD | 88 | F | 6 | NA | 8 |
2676 | AD | 87 | F | 6 | NA | 6.5 |
2381 | AD | 55 | F | 6 | NA | 15 |
1658 | AD | 102 | F | 4 | 2/3 | 2 |
2148 | AD | 78 | F | 6 | NA | 8 |
2187 | AD | 85 | F | 6 | 3/4 | 14.5 |
2447 | AD | 65 | M | 6 | NA | 11 |
2423 | AD | 89 | F | 6 | NA | 7 |
2344 | AD | 86 | M | 5 | 2/3 | 5 |
2105 | AD | 89 | M | 6 | NA | 9.5 |
2733* | AD | 75 | M | 5 | NA | 13 |
2636* | AD | 78 | M | 5 | NA | 5 |
Notes: Braak stage: A measure of the number and location of tau tangles and β-amyloid plaques in the brain. PMD: Post-mortem delay. NA: Not available. Cases indicated by asterisk were used for the GeoMx WTA analyses.